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Abstract
Background: Non-melanoma skin cancers are one of the most common human malignancies accounting for 2–3% of
tumors in the US and represent a significant health burden. Epidemiology studies have implicated Tp53 mutations triggered
by UV exposure, and human papilloma virus (HPV) infection to be significant causes of non-melanoma skin cancer.
However, the relationship between Tp53 and cutaneous HPV infection is not well understood in skin cancers. In this study
we assessed the association of HPV infection and Tp53 polymorphisms and mutations in lesional specimens with squamous
cell carcinomas.
Methods: We studied 55 cases of histologically confirmed cutaneous squamous cell carcinoma and 41 controls for the
presence of HPV infection and Tp53 genotype (mutations and polymorphism).
Results: We found an increased number of Tp53 mutations in the squamous cell carcinoma samples compared with
perilesional or control samples. There was increased frequency of homozygous Tp53-72R polymorphism in cases with
squamous cell carcinomas, while the Tp53-72P allele (Tp53-72R/P and Tp53-72P/P) was more frequent in normal control
samples. Carcinoma samples positive for HPV showed a decreased frequency of Tp53 mutations compared to those without
HPV infection. In addition, carcinoma samples with a Tp53-72P allele showed an increased incidence of Tp53 mutations in
comparison carcinomas samples homozygous for Tp53-72R.
Conclusions: These studies suggest there are two separate pathways (HPV infection and Tp53 mutation) leading to
cutaneous squamous cell carcinomas stratified by the Tp53 codon-72 polymorphism. The presence of a Tp53-72P allele is
protective against cutaneous squamous cell carcinoma, and carcinoma specimens with Tp53-72P are more likely to have
Tp53 mutations. In contrast Tp53-72R is a significant risk factor for cutaneous squamous cell carcinoma and is frequently
associated with HPV infection instead of Tp53 mutations. Heterozygosity for Tp53-72R/P is protective against squamous cell
carcinomas, possibly reflecting a requirement for both HPV infection and Tp53 mutations.
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Introduction
Non-melanoma skin cancer (NMSC) is now the most common
cancer among Caucasians, outnumbering the total of all other
cancers combined [1]. While little mortality is associated with
NMSC, these cancers constitute a major public health problem
[1,2,3] associated with a high, and increasing financial burden
[4,5]. The pathogenesis of NMSC remains unclear. Epidemiolog-
ical studies have identified many risk factors for cutaneous NMSC
including UV exposure, fair complexion, older age, male sex,
smoking, chronic skin ulcers and burn scars, exposure to ionizing
radiation or arsenic, and immunosuppression. The importance of
UV-irradiation in the development of cutaneous squamous cell
carcinoma (SCC) is well established, and studies of premalignant
actinic keratosis (AK) lesions and experimental skin cancers in
mice suggest that a key event in the development of skin SCC is
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gene mutations, characteristically (C to T or CC to TT) transitions
at dipyrimidine sites [6,7,8]. The ability of UV-irradiation to
induce Tp53 mutations is important as the Tp53 gene plays a
critical role in apoptosis, cell proliferation, and DNA repair.
Mutations in this gene are among the most common mutations
observed in human tumors, including SCC [9]. However, while
inactivating Tp53 mutations are present in from 15% to over 90%
of SCCs and precursors lesions [6,10,11,12,13], these mutations
are also common in histologically normal skin, where they have
been detected (using a variety of approaches) in 7% to 50% of
samples [11,14]. In addition, increased risk for SCC has not been
a prominent feature of individuals with Li Fraumeni syndrome,
which is characterized by the presence of mutations of both Tp53
alleles [15], suggesting that factors in addition to Tp53 mutations
are required for the development of SCC.
Over the last 10 years there has also been increasing interest in
the potential role of cutaneous human papillomavirus (HPV) in the
development of SCC. However, whether certain HPVs play a role
in development of skin SCC, and if so, how, is not well
understood. Data supporting a role for cutaneous HPV in the
development of skin SCC include a high rate of malignant
transformation (i.e. development of SCC) of sun-exposed skin
warts among subjects with either inherited immunosuppression
(such as patients with epidermodysplasia verruciformis (EV), who
lack the ability to control infection with specific cutaneous HPVs
[16]), or iatrogenic immunosuppression (e.g. renal transplant
recipients receiving immunosuppression [17]. Among immuno-
competent subjects, detection of HPV in cutaneous SCCs has
ranged from 27 to 70% [18,19], depending on the specific PCR
consensus primers employed. Several recent serologic studies using
a multiplex assay have detected a higher rate in seropositivity
among squamous cell carcinoma patients than among controls or
basal cell carcinoma patients [20,21,22,23]. In many of these
studies there was a significant increase in seropositivity for b-HPV
[23,24,25] and c-HPV [25] in SCC patients, while other studies
failed to identify the corresponding viral genomes using PCR [26].
In a previous case-control study we used a comprehensive
approach for detection of HPV (employing three different PCR
based protocols) to examine the relationship between the presence
of specific types of HPV infection and SCC. We reported that
detection of HPV DNA was high in both case lesions (54%) and
perilesions (50%) and in both sun-exposed normal tissue (59%)
and non-sun-exposed normal tissue (49%) from controls. Howev-
er, HPV DNA from b-papillomavirus species 2 was more likely to
be identified in tumors than in adjacent healthy tissue among cases
(paired analysis, odds ratio= 4.0, confidence interval= 1.3–12.0)
[27]. The high prevalence of b-papillomavirus species in SCC has
also been noted in some [23,28,29,30,31], but not all studies
[18,32].
Laboratory based studies suggest that certain Tp53 polymor-
phisms may also play a role in the pathogenesis of NMSC. A
common Tp53 polymorphism located at codon 72 (encoding
either a proline or arginine residue), within a conserved proline
rich SH3 binding domain, is known to be critical for promoting
apoptosis [33,34], and laboratory based studies have demonstrated
functional and biologic differences between the two polymorphic
forms [35,36,37,38,39,40,41]. The codon 72 polymorphism has a
well-characterized geographic distribution, with the frequency of
Tp53-72R increasing with geographic distance from the equator.
The allelic frequency varies widely between ethnic populations,
with fair skin northern European populations having a higher
frequency of the Tp53-72R allele [42]. Recent epidemiologic
studies have reported an association between esophagus, lung, and
gastric cancers and this Tp53 codon 72 polymorphism
[43,44,45,46,47,48]. Initial studies reported that Tp53-72R was
more susceptible to HPV-18 E6 mediated degradation than the
Tp53-72P, and suggested that Tp53-72R is a risk factor for high
risk HPV mediated cervical carcinoma [49]. However, many
subsequent studies did not confirm these results [50]. Conflicting
data exists on Tp53 codon 72 polymorphisms in non-melanocytic
skin carcinomas (NMSCs): while some studies suggested that
Tp53-72R is a risk factor for developing cutaneous SCC in
immunosuppressed patients with epidermodysplasia verruciformis
(EV) [51] or in post-transplant individuals [52,53,54], others did
not [55,56,57,58]. Further, recent studies have reported finding a
relationship between melanoma and this polymorphism, but not in
NMSC [59,60,61,62].
While previous studies have examined the relationships between
NMSC and HPV infection, or NMSC and UV-induced Tp53
mutations and polymorphisms, to our knowledge, none have
examined all these factors in one study. In the present study, we
examined the relationship between HPV infection, Tp53 muta-
tions and Tp53 codon 72 polymorphisms in tissue biopsies of
tumor and surrounding histologically normal skin from patients
with NMSC, and from sun exposed and non-sun exposed tissue of
individuals without NMSC. We hypothesize that several different
pathways lead to the development of NMSC.
Materials and Methods
Study Population, Interview, and Physical Examination
The inclusion and exclusion criteria, subject recruitment,
interview procedures, physical examination, and collection of
specimens have been previously described [27]. Briefly, immuno-
competent Caucasian men and women over the age of 55 years
without a history of genetic syndromes associated with increased
susceptibility to damage from UV exposure (Xeroderma pigmen-
tosum, nevoid basal cell syndrome, albinism, epidermodysplasia
verruciformis, epidermolysis bullosa dystrophica, dyskeratosis
congenital), or exposure to psoralen with UV light treatment,
were eligible. Digit and mucosal lip lesions were also excluded. All
subjects provided informed consent according to procedures
approved by the Institutional Review Boards of the University of
Washington.
The present study population consisted of 55 patients (cases)
and 41 controls on whom detection and sequencing of Tp53
mutations was conducted. Of the 96 study subjects, 48 (18 cases
and 30 controls) were included in our previous report regarding
HPV and SCC [27]. Cases were individuals with histologically
confirmed cutaneous SCC who were undergoing surgical resection
at the University of Washington Medical Center, the VA Puget
Sound Health Care System, Group Health Cooperative, or Skin
Surgery Center. Controls were individuals without a prior history
of skin cancer recruited by a letter sent from their primary care
providers. All control subjects had a full skin examination of their
face, neck, scalp, ears, back, torso, buttocks, arms, and legs
performed by a dermatologist (MMA). Those persons with lesions
suspicious for SCC were deemed ineligible and referred for further
evaluation. All participants completed a standardized interview to
collect information pertaining to potential confounding variables
including: (i) age, sex, ethnicity, income, and exposure to tobacco
smoke, arsenic, hydrocarbons, or radiation; (ii) propensity to
sunburn and freckle; (iii) history of pertinent dermatological
conditions, including actinic keratosis, burn scars, ulcers, and
warts; and (iv) lifetime history of sun exposure, including a history
of tanning bed use, and number of blistering sunburns.
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For cases, a portion of the residual SCC along with adjacent
clinically uninvolved perilesional skin was collected from each
subject. For controls, punch biopsies of clinically normal skin were
obtained from a sun-exposed (pre-auricular) site as well as from a
sun-protected site from the upper inner arm as previously
described. One third of the biopsy was placed in 10% neutral
buffered formalin for histopathology, another third placed into
specimen transport media (STM, Qiagen), and the final portion
placed into ethanol.
Histopathology and Detection of HPV Infection
Routine paraffin-embedded tissue was prepared from the biopsy
specimens and then sectioned and stained with hematoxylin and
eosin to confirm the diagnosis. HPV was detected by PCR and
typed as previously described using three protocols to assure
detection of all HPV types [27].
Detection and Sequencing of Tp53 Mutations and
Polymorphism
Since our goal was to identify major Tp53 mutations that are
likely involved in the pathogenesis of neoplasia, we focused on
identifying clonal mutations (most abundant in neoplastic or pre
neoplastic tissue), rather than sub-clonal mutations (present at
lower frequencies). To this end we directly sequenced coding
sequence (cDNA) amplified from tissue specimens without
employing a clonal enrichment steps [63]. The mRNA was
extracted from freshly frozen biopsies using TRIzol reagent
(Invitrogen) according to the manufacturer protocol. Briefly, the
frozen tissue was homogenized in TRIzol reagent and incubated at
RT for 5 minutes. The homogenate was centrifuged to pellet
polysaccharides and lipids. Chloroform was then added to the
supernatant, mixed and centrifuged. The RNA in the upper
aqueous phase was isolated by ethanol precipitation. The mRNA
template was transcribed into cDNA with MLV reverse
transcriptase, using p53 specific primers. Nested PCR reactions
were carried out to amplify an 873 bp fragment from exon 4 to
exon 8, spanning the region that encodes most of the allelic
polymorphisms and reported mutations (Table S1). Two negative
controls (reaction mix without cellular DNA) were included in
each set of reactions to monitor potential contamination. PCR
products were isolated by anion exchange using the QIAEX II gel
extraction kit (Qiagen Inc., Chatsworth, CA) and 50–100 ng of the
PCR product was sequenced using ABI PRISM
TM Dye
Terminator Cycle Sequencing kit (Perkin-Elmer Cetus) on an
Applied Biosystem Model 373A DNA sequencing system (Applied
Biosystems Inc.). Each sequence was determined bidirectionally
using the nested primers (Table S1). Resulting sequences were
analyzed with Sequencher
TM (Gene Codes Corp., Ann Arbor, MI)
and compared to the wild type Tp53 sequence.
Tp53 sequence was evaluated for the presence of either non-
synonymous (altering the amino acid sequence), synonymous (no
change in amino acid sequence) mutations and UV damage
signature (transitions at dipyrimidine sites, C.T or tandem
CC.TT) [6]. Determination of the common Tp53 polymorphism
alleles at codon 72 was from direct sequencing of the cDNA
amplicon. Tp53 polymorphism at codon 72 present in lesional (i.e.
tumor) and perilesional (i.e. normal) tissues in cases, and in sun
exposed and non sun exposed tissue in the controls was conserved
with discrepancy in only 3 of the 55 paired lesional/perilesional
samples, possibly due to loss of heterozygosity (LOH) or
preferential allelic expression. Hotspot mutations were defined as
those categorized as signatures of UV damage and occurring
frequently in NMSCs [6,8,12], they included Arg248Trp, Arg196-
Stop, and His179Stop.
Statistical Methods
Differences between cases and controls were assessed using chi-
square analyses to compare categorical variables and Student’s t-
test to compare continuous measures. Associations with ordinal
factors, such as propensity to sunburn, were evaluated with
Mantel-Haenszel tests for trends. Fisher’s exact tests were utilized
when cell frequencies were less than 5. To evaluate differences in
categorical measures by site of the skin tissue, paired samples from
within a subject were compared using McNemar’s Test.
A two-sided 0.05 level test determined statistical significance for
all analyses. All analyses were conducted using SAS 9.1 (SAS
Institute Inc., Cary, NC).
Results
The characteristics of the study population including 55 subjects
with and 41 without cutaneous SCC are presented in Table 1.
Overall, the patients were primarily elderly immunocompetent
males. The cases and controls were similar regarding gender,
history of smoking, and family history of skin cancer. However, the
case population was slightly older and had an increased propensity
to sunburn compared to the control population.
Frequency of Tp53 Mutations in Lesional, Perilesional and
Control Samples
Among cases, the frequency of any Tp53 mutation was
significantly increased in the lesional samples (33%) as compared
to perilesional samples (16%). However, Tp53 mutations were rare
in both sun exposed (2%) and sun protected (5%) control tissues
(Table 2). Identification of more than one type of Tp53 mutation
was noted in 7% of lesional samples, 2% of perilesional samples,
5% of sun protected tissue from controls and 0% from sun-
exposed areas from controls.
Characterization of the specific type of Tp53 mutations showed
that 17 of 18 lesional tissues with Tp53 mutations were non-
synonymous mutations (resulting in amino acid changes), and 13
of these had mutations with a UV damage signature (i.e., C.To r
tandem CC.TT transitions at dipyrimidine sites). 8 of 9 Tp53
mutations from perilesional tissue were non-synonymous, with 7
exhibiting a UV damage signature. The single Tp53 mutation
identified in the sun-exposed control was synonymous (no amino
acid change), while the two mutations identified in the sun-
protected controls were non-synonymous mutations with a UV
damage signature. Among tumor tissues with Tp53 mutations, 11
of 18 (61%) were previously reported ‘‘hotspot’’ mutations, while
among perilesional tissues 4 of 9 (44%) were ‘‘hotspot’’ mutations.
Surprisingly only 1 of 5 (20%) of the lesional and perilesional
tissues showed concordant Tp53 mutations.
Tp53 Pro-72 Polymorphism in Cases and Controls
Since, as mentioned above some [61], but not all [50,58],
previous studies have demonstrated an association between the
polymorphism at codon Tp53-72 and the development of cancer,
we examined the distribution of the common Tp53 codon-72
polymorphism among the case and controls (Table 3). The
presence of at least one Tp53-72P allele (Pro/Pro or Pro/Arg) was
significantly higher in the control population (59%) when
compared to the SCC population (36%). The presence of at least
one Tp53-72R did not differ between SCC (93%) and control
(88%) populations.
Tp53 Variants and HPV in Squamous Cell Carcinomas
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In the present study, 66% of the lesional samples, 55% of the
perilesional samples, 60% of the sun-exposed control samples, and
51% of the sun-protected control samples had detectable HPV
DNA. Although we previously reported that HPV b-papilloma-
virus species was differentially detected in lesional (tumor) as
compared to perilesional tissue in the larger sample set, there was
no difference between lesional, perilesional and control tissues with
respect to the specific types of HPV present in this smaller sample
set. Interestingly, detection of HPV was inversely associated with
the presence of Tp53 mutations among lesion tissues (Table 4).
While Tp53 mutations were present in 50% of the HPV negative
cancers, they were only detected in 23% of HPV positive cancers
(p=0.045). Among perilesional tissues, Tp53 mutations were at
similar frequencies in HPV negative samples (4/24, 17%) and in
HPV positive samples (6/29, 21%) (data not shown).
Relation between Codon 72 Polymorphism, HPV
Infection and Tp53 Mutations in Cutaneous Squamous
Cell Carcinoma
Given the above findings, we asked whether the role of Tp53
mutations and of HPV infection in the pathogenesis of SCC might
vary with a specific polymorphism at Tp53-codon 72 (Table 5).
Among lesion tissues, the detection of HPV was not statistically
different among patients with (12/20, 60%) or without (23/33,
70%) the Tp53-72P polymorphism. In contrast, Tp53 mutations
were more likely to be detected from individuals having a Tp53-
72P allele (11/20, 55%) as compared to those without (7/35, 20%)
(p=0.0078). Similarly, in perilesional tissues, Tp53 mutations
were detected in 7 of 19 (37%) patients who had a Tp53-72P
polymorphism as compared to 2 of 36 (6%) without Tp53-72P.
However, HPV DNA was detected at similar frequencies from
those with (11/19, 58%) or without a Tp53-72P polymorphism
(18/34, 53%) (Table 6). No significant difference in the frequency
of Tp53 mutations was detected in control individuals with or
without the Tp53-72P polymorphism.
Table 7 summarizes the relationship between the presence of
HPV DNA, Tp53 mutations and Tp53-72P status. Most cancers
(44/53, 86%) contained either HPV or Tp53 mutations. While
there was increased detection of Tp53 mutations in SCC arising
among those with (11/20, 55%), as compared to those without (6/
33, 18%) a Tp53-72P polymorphism (p=0.005), detection of HPV
was similar among patients with (12/20, 60%) or without (23/33,
70%) the Tp53-72P polymorphism. However, in patients without
Tp53 mutations, HPV DNA was somewhat less likely detected in
patients with (7/20, 35%), as compared to those without (20/33,
61%) the codon-72P polymorphism (p=0.07). Samples from
patients heterozygous for codon-72R/P were somewhat more
likely to contain both HPV DNA and Tp53 mutations (5/16,
31%) and were somewhat less likely to be negative for HPV DNA
and Tp53 mutations (1/16, 6%; p=0.07).
Discussion
Non-melanoma skin cancers are frequent tumors that arise from
a complex interaction between environmental, immunologic and
genetic factors [64,65]. The multifactorial nature of these cancers
has led to much controversy and speculation with regard to
etiologic mechanisms. The aim of this study was to better define
the causal association of HPV infection and the tumor suppressor
gene Tp53 (polymorphism and mutations) in cutaneous squamous
cell carcinomas. We found a significant increase in the frequency
of Tp53 mutations in carcinoma and perilesional samples
compared to controls, with the majority of these mutations being
non-synonymous changes. In contrast, the majority of samples
were positive for HPV infection, determined by the extremely
sensitive PCR assay. There was only a moderate increase in the
incidence of HPV infection in the carcinomas above the high
steady state level detected in perilesional or control samples. There
was, however, an inverse correlation between the presence of HPV
and Tp53 mutations in the carcinoma specimens; 50% of HPV
negative carcinomas had Tp53 mutations while only 23% of the
HPV positive specimens had Tp53 mutations. These results
suggest that two distinct molecular pathways either HPV infection
or Tp53 mutations may drive carcinogenesis. We further found
Table 1. Demographic and Skin Characteristics of Cases with Squamous Cell Carcinoma and Controls.
Cases with SCC (n=55) Controls (n=41) P-value
Age (mean years ± sd) 74.5 69.9 0.02
Age 0.08
,70 17 (31%) 21 (51%)
70–79 21 (38%) 11 (27%)
$80 17 (31%) 9 (22%)
Female Gender 2 (4%) 5 (12%) 0.13
Ever Smoker 42 (76%) 31 (76%) 0.93
Family Hx of Skin Cancer 10 (20%) 5 (13%) 0.39
Propensity to Sunburn 48 (87%) 25 (61%)* 0.003
Propensity to Sunburn 0.001
Burns, blisters 14 (25%) 5 (12%)*
Burns, no blisters 18 (33%) 4 (10%)
Mild burn, tans 16 (29%) 16 (39%)
No burn, tans 4 (7%) 13 (32%)
No burn, no tan 3 (5%) 3 (7%)
doi:10.1371/journal.pone.0034422.t001
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correlated with the identity of the common codon-72 Tp53
polymorphism. Homozygosity for the Tp53-72R allele was a
significant risk factor for the development of squamous cell
carcinomas. Among patients with SCC, the presence of Tp53-72P
allele was associated with Tp53 mutations, while the lack of Tp53-
72P allele was associated with HPV infection. Patients heterozy-
gous for Tp53-72R/P are associated with an increased frequency
of both Tp53 mutations and HPV infections.
Tp53 Mutations and Cancer
As expected there was an increase in the frequency of Tp53
mutations in the tumors compared with either the perilesional or
control specimens. Most of the Tp53 mutations present in the
cancers were non-synonymous changes and many were previously
characterized ‘‘hotspots’’ that showed signatures of UV damage
suggesting exposure to sunlight is a primary environmental insult
causing the mutations [6,8,12]. The most frequently identified
mutations were Arg248Trp, His179Tyr and Arg196Stop. Tp53-
Arg248Trp is a common UV damage-associated mutation that
arises from CC.TT transition at a dipyrimidine site that spans
two adjacent codons mutations. Arg248Trp (R248W) disrupts
DNA binding and gain of function effect in Tp53 null cells,
promoting tumorigenesis in nude mice and growth in soft agar
[66]. Tp53-His179Tyr maps to the conserved L2 loop and has
been shown to prevent zinc binding resulting in a non-functional
protein [67,68,69]. Tp53-Arg196Stop is a nonsense mutation
resulting in premature termination and the generation of an
inactive protein [68,69]. In contrast, most of the Tp53 mutations
identified in the control samples were silent synonymous changes
that do not alter the amino acid residues. The presence of non-
synonymous mutations in the carcinoma suggests that the Tp53
mutations provide the cell with a selective growth advantage by
inhibiting apoptosis and promoting genetic instability. On the
other hand, Tp53 mutations in the control samples were random
passenger mutations that did not confer a selective growth
advantage. It is possible that some of the silent Tp53 passenger
mutations in the normal control skin may represent rare heritable
variants since normal non-skin tissue was not available for
comparison.
For this study we were interested in identifying the most
prevalent p53 mutations that might represent driver mutations
promoting SCC. Therefore we choose to use direct cDNA
sequencing without a clonal enrichment step such as denaturing
high-performance liquid chromatography (DHPLC). This proce-
dure allows for greater specificity in identifying clinically relevant
mutations that promote carcinogenesis. However this approach
does not detect every p53 mutation present in the sample since
small subclonal mutations would not be identified without a clonal
enrichment step. In addition, our sequencing strategy targeted
exon 4 to exon 8, spanning the region that encodes most of the
allelic polymorphisms and reported mutations. P53 mutations
occurring outside of this region would not be detected in this study.
Predominant mutations in Tp53 were readily identified in tumors
representing a clonal population of cells sharing identical Tp53
mutations. Presumably, p53 sequences amplified from control and
perilesional samples were heterogeneous and contained subclonal
Tp53 mutations amid a background of wild-type Tp53 sequences;
minor Tp53 mutations were not detected by direct sequencing.
The frequency of Tp53 mutations detected in the perilesional and
control specimens were lower than that reported in other studies
focusing on squamous cell carcinomas that employed a clonal
enrichment procedure [70].
In a recent study Durinck et al. determined the temporal
sequence of acquired genetic abnormalities during tumor
progression by using a combination of DNA sequence and copy
number variations [71]. They conclude that the development of
most tumor-associated mutations in squamous cell carcinoma are
gated by the elimination of the wildtype p53 allele (LOH).
Unfortunately the methodology used in our studies (cDNA
Table 3. Codon-72 Polymorphism in Cases and Controls.
Cases (lesions) (n=55) Controls (sun-exposed) (n=41) P-value
Polymorphism 0.10
Pro/Pro 4 (7%) 5 (12%)
Pro/Arg 16 (29%) 19 (46%)
Arg/Arg 35 (64%) 17 (41%)
Any Proline (Pro/Pro or Pro/Arg) 20 (36%) 24 (59%) 0.03
doi:10.1371/journal.pone.0034422.t003
Table 4. Tp53 mutations and Detection of HPV DNA in Lesional Samples of Cases with SCC.
Type of Tp53 Mutation HPV DNA Positive HPV DNA Negative P-value
Any mutation(s) 8/35 (23%) 9/18 (50%)* 0.045
Non-synonymous coding mutation(s) 8/35 (23%) 9/18 (50%)* 0.045
UV-damage CRTo rC C RTT transition mutation(s) 5/35 (14%) 7/18 (39%)* 0.08
‘‘Hotspot’’ mutation(s) 5/35 (14%) 6/18 (33%) 0.15
Arg248Trp 3/35 (9%) 1/18 (6%) 1.00
Arg196Stop 1/35 (3%) 1/18 (6%) 1.00
His179Stop 1/35 (3%) 3/18 (17%) 0.11
doi:10.1371/journal.pone.0034422.t004
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the mutated template was visible in the vast majority of the
mutations identified in the lesion and perilesions specimens and
thus is either homozygous (LOH) or reflects the preferential
expression of the mutant allele.
Of the 56 paired samples (lesional and perilesional) only 5 had
Tp53 mutations identified in both tissues and only 1 (20%) shared
the same mutation. The lack of tumor-specific p53 mutations in
the adjacent perilesional is probably due to sampling bias and the
limited sensitivity of direct cDNA sequencing. Ren et al. found
that benign clonal keratinocyte patches with p53 mutations
showed no genetic correlation to adjacent squamous cell
carcinomas. These authors suggest the p53 expressing keratinocyte
patches result form clonal expansion of cells with p53 mutations
that may be permissive for a subsequent event driving carcino-
genesis. In the vast majority of cases these p53 mutations do not
represent precursor mutations present in the adjacent carcinomas
[11,72]. Alternatively, the causal Tp53 mutations may be late
events in carcinogenesis and may not be present in the adjacent
precursor lesions. Additional studies using more sensitive meth-
odology are required to identify the presence of tumor specific p53
mutations in adjacent perilesional biopsies.
HPV Infection and Cancer
Although direct causal association between HPV and cervical
carcinoma has been well established [73,74,75], the association
between HPV and cutaneous squamous cell carcinomas is less well
defined. In our previous studies the high prevalence and
widespread distribution of HPV species made it statistically
difficult to associate the causal link between selective HPV
genotypes and squamous cell carcinomas. The prevalence of
HPV DNA in the tumors was not significantly elevated above the
high level present in the control samples [27]. In addition there
was no differential detection of HPV DNA across various HPV
types [27]. However, we and others [76] found that HPV DNA
from b-papillomavirus species 2 was more likely to be present in
tumors than adjacent healthy tissue, suggesting that certain HPV
types may be involved in the progression of cutaneous SCCs. The
current study supports the results of the previous study in that
there was no significant increase in HPV DNA in cases (66%)
compared to either perilesional (55%) or control samples (60%).
These results suggest that in most cases HPV infection alone is not
sufficient to promote carcinogenesis; additional factors such as
perhaps immunosuppression or additional genetic modifications
are required. While some serological studies have shown that
patients with correlated detection of HPV antibodies and b-
papillomavirus have increased risk of developing squamous cell
carcinoma [20], other studies have shown a lack of correlation
between the presence of HPV DNA and antibodies suggesting the
antibody may have arisen from a remote site or prior infection
[26]. In addition, a recent study employing transcriptome
sequencing failed to detect HPV gene expression in squamous
cell carcinomas suggesting that papillomavirus expression is not a
factor in maintenance of cutaneous SCC [77]. In our study HPV
detection was based on an extremely sensitive PCR assay that did
not provide information on viral load, transcriptional activity, or
viral integration that could help to determine the role of HPV in
cutaneous carcinogenesis. It is also likely that specific cutaneous
HPV types are more pathogenic than others; however, a larger
clinical study is required to identify the more pathogenic types.
Incidence of HPV Infection and Tp53 Mutations
We hypothesized that HPV infection and Tp53 mutations
would be increased in carcinoma samples with a positive and
cooperative association in promoting carcinomas. Instead, we
found an inverse association; HPV positive tumors had a lower
Table 5. Relationship between Codon-72 polymorphisms, HPV, and Tp53 Mutations in Lesional Samples.
Proline-72 Positive (CC or CG) Proline-72 Negative (GG) P-value
HPV positive 12/20 (60%) 23/33 (70%) 0.47
Any Tp53 mutation(s) 11/20 (55%) 7/35 (20%) 0.008
Non-synonymous coding mutation(s) 11/20 (58%) 6/35 (17%) 0.004
UV-damage CRTo rC C RTT transition mutation(s) 8/20 (40%) 5/35 (14%) 0.048
‘‘Hotspot’’ mutation(s) 7/20 (35%) 4/35 (11%) 0.08
Arg248Trp 2/20 (10%) 2/35 (6%) 0.62
Arg196Stop 2/20 (10%) 0/35 (0%) 0.13
His179Stop 3/20 (15%) 1/35 (3%) 0.13
doi:10.1371/journal.pone.0034422.t005
Table 6. Relationship between Codon-72 polymorphisms, HPV, and Tp53 Mutations in Perilesional Samples.
Proline-72 Positive
(Pro/Pro or Pro/Arg)
Proline-72 Negative
(Arg/Arg) P-value
HPV Positive 11/19 (58%) 18/34 (53%) 0.73
Any Tp53 mutation(s) 7/19 (37%) 2/36 (6%) 0.005
Non-synonymous coding mutation(s) 7/19 (37%) 1/36 (3%) 0.002
UV-damage CRTo rC C RTT transition mutation(s) 6/19 (32%) 1/36 (3%) 0.005
‘‘Hotspot’’ mutation(s) 4/19 (21%) 0/36 (0%) 0.01
doi:10.1371/journal.pone.0034422.t006
Tp53 Variants and HPV in Squamous Cell Carcinomas
PLoS ONE | www.plosone.org 7 April 2012 | Volume 7 | Issue 4 | e34422incidence of Tp53 mutations (23%) in comparison to HPV
negative tumors (50%). This inverse association was not present in
perilesional or control samples suggesting that this relationship
pertains to the induction of tumors. The simplest explanation for
these results is that two potential separate pathways either
dependent on HPV infection or on Tp53 mutation lead to
cutaneous squamous cell carcinoma. HPV infection may decrease
the incidence or necessity of Tp53 mutations, and Tp53 mutations
may inhibit HPV infection or the proliferation of HPV infected
cells. A similar inverse correlation has been reported in
oropharyngeal squamous cell carcinomas [78] and head and neck
carcinomas [79,80,81] in which HPV positive tumors were
associated with wild type TP53 and HPV negative tumors had a
higher frequency of Tp53 mutations. In contrast, recent in vitro
studies have shown that expression of wt Tp53 can inhibit HPV
replication by blocking the expression, and promoting the
degradation of HPV20 E6 [82], while the common hot spot
mutation R248W confers a protective effect on the HPV20 E6
protein to promote viral replication [83].
Although the E6 and E7 proteins encoded by cutaneous HPVs
do not bind or target Tp53 or RB protein for degradation [84], the
E6 protein encoded by b-papillomavirus does bind and inactivate
the pro-apoptotic protein BAK [85]. The elimination of BAK
inhibits apoptosis, resulting in a partial downstream block of Tp53
function, which may abrogate the need for Tp53 inactivation by
mutation or degradation [86].
Tp53-72R/P Polymorphism Association with Squamous
Cell Carcinoma
By stratifying patients based on the status of the common Tp53
polymorphism at codon-72(R/P) we identified several additional
statistically significant associations that lead to important mech-
anistic predictions. The lack of Tp53-72P (Tp53-72R/R) was a
significant risk factor for SCC in the study population of elderly
white male patients. Tumors without Tp53-72P (Tp53-72R/R)
had fewer Tp53 mutations with a small non-significant increase in
HPV DNA. These results suggest that patients homozygous for
Tp53-72R are more likely to develop cutaneous squamous cell
carcinoma with HPV infection and without Tp53 mutations.
These results resemble those reported for SCC arising in
immunosuppressed patients. It is well documented that there is
an increased incidence of skin cancers in selective immunosup-
pressed patient populations (solid organ transplant and epidermo-
dysplasia verruciformis (EV)) attributed to potential infectious or
immune-modulatory factors [87]. Persons afflicted with EV, an
inherited disorder of cell immunity, are unable to control
cutaneous HPV infection leading to flat, atypical warts that
eventually undergo malignant transformation [87,88]. Solid organ
transplant patients also develop a large number of warts that carry
a high risk of malignant transformation [18]. Studies focusing on
cutaneous malignancies arising in these immunosuppressed patient
populations have reported the lack of Tp53-72P to be an
additional risk factor for developing squamous cell carcinoma
[89,90]. In our study population of elderly white males presumably
with weakened immune systems, the lack of Tp53-72P is a risk
factor for developing SCC frequently associated with HPV DNA.
These results are in accord with recent studies in head and neck
carcinomas that showed the risk of HPV mediated tumorigenesis
increased with the numbers of Tp53-72R alleles [79].
The codon-72 polymorphism is located in a highly conserved
proline rich domain involved in DNA binding, and several studies
show clear functional differences between the two isoforms.
Expression of the Tp53-72R in p53-null cells induced enhanced
apoptosis possibly related to increased localization of the arginine
variant to the mitochondria compared to the proline variant [34].
In addition, the Tp53-72R isoform binds more strongly to the
proly-isomerase PIN1 resulting in increased p53 acetylation and
dissociation from the apoptosis inhibitor iASPP than the Tp53-
72P form [91], supporting the view that Tp53-R72 is a more
potent inducer of apoptosis than Tp53-P72. The enhanced tissue
specific apoptotic potential of the Tp53-72R variant was recently
confirmed in mouse models for the codon-72 Tp53 polymorphism
[37,40]. Cell culture based studies particularly in dermal
fibroblasts derived from centurions [92] have shown that
expression of the Tp53-72P variant results in growth arrest and
senescence due to increased ability to transactivate p21/waf1 [41].
Cell expressing the Tp53-72P variant also are more efficient at
specifically activating several Trp53-dependent DNA-repair target
genes and are associated with a higher DNA repair capacity than
cells expressing the Tp53-72R allele [93]. The current consensus is
that Tp53-72R is more effective at inducing apoptosis and
protecting stressed cells from neoplastic development while
Tp53-72P is more effective at inducing cell cycle arrest and
senescence.
Similar to the cell cycle studies the association of the common
Tp53 polymorphisms at codon-72 with cancer risk has been
extensively studied for multiple cancers with mixed and inconsis-
tent results. There are over 230 studies in the NIH genetic
association database evaluating the effect of the codon-72
polymorphism on susceptibility to a wide variety of cancers with
many reporting ‘statistically significant’ associations [50]. Of the
studies that report a significant tumor association, the majority
claim Tp53-72P to be a risk factor for developing malignancy
[94,95] or to be associated with higher stage of disease or poor
prognostic outcome [96]. A smaller subset of studies reported
Tp53-72R to be a risk factor for the development of cancer in
immunocompetent [97] and immunosuppressed patients [98]. In
contrast, many other studies have failed to identify a significant
association between the polymorphism and cancer [50]. The
variability in results is attributed to the multifactorial etiology of
cancer and study participant characteristics since the Tp53
polymorphism varies widely among ethnic groups.
Table 7. HPV DNA and Tp53 Mutations Vary by Codon-72 Polymorphisms in Skin Cancer.
Proline 72 positive (Pro/Pro) Proline 72 positive (Pro/Arg) Proline 72 negative (Arg/Arg)
Neither 1/4 (25%) 1/16 (6%) 7/33 (21%)
HPV, no Mutations 1/4 (25%) 6/16 (38%) 20/33 (61%)
Mutations, No HPV 2/4 (50%) 4/16 (25%) 3/33 (9%)
HPV and Mutations 0/4 (0%) 5/16 (31%) 3/33 (9%)
doi:10.1371/journal.pone.0034422.t007
Tp53 Variants and HPV in Squamous Cell Carcinomas
PLoS ONE | www.plosone.org 8 April 2012 | Volume 7 | Issue 4 | e34422Tp53-72R and HPV Associated Carcinomas
Among the carcinomas without detectable Tp53 mutations
there was a non- significant trend toward an increased frequency
of HPV infection in tumors lacking Tp53-72P (Table 7). This
trend was not present when tumors with Tp53 mutation were
included and suggests that the effect of HPV infection in
promoting carcinomas is greatest in cells without Tp53-72P
isoforms or Tp53 mutations. This suggests that the role of HPV in
promoting carcinomas may be through inhibiting the Tp53
pathway and that cells expressing mutant Tp53 and Tp53-72P
may not be less susceptible to HPV induced carcinogenesis. The
selective role of HPV in homozygous Tp53-72R/R carcinomas
may be related to the increased and altered capacity of that
polymorphic isoform to induce apoptosis by direct mitochondrial
binding [34] that may be partially inhibited by HPV infection
[99]. The association of HPV with cells homozygous for Tp53-
72R/R is probably not due to permissive replication of the virus in
these cells since we showed there was no significant increase in
HPV detected in homozygous Tp53-72R/R perilesional and
control specimens.
Our results show that tumors expressing the Tp53-72P
polymorphism showed an increased frequency of Tp53 mutations
(55%) in comparison to tumors without Tp53-72P (20%)
consistent with studies in lung carcinoma [100] [47]. These results
may reflect a selective growth advantage imparted to Tp53-72P
cells expressing mutant forms of Tp53 or may reflect a mutator
phenotype resulting in enhanced genome wide mutations. Studies
have shown that the expression of the Tp53-72P allele in
Glioblastoma [101], ovarian carcinoma [102], and head and neck
carcinoma [103] is associated with more aggressive disease and a
shorter survival.
In a recent study, Guan et al. showed that ARID1a, a tumor
suppressor gene involved in chromatin remodeling and frequently
mutated in a wide variety of tumors binds to p53 [104]. The p53/
ARID1a complex is required to direct the transcription of several
p53 inducible genes. In addition, they show a mutually exclusive
pattern of Tp53 and ARID1a mutations, with wild-type p53
tumors containing mutant ARID1a and mutant p53 tumors
containing wildtype ARID1a. It will be important to investigate
the status of ARID1a in squamous cell carcinomas and to
determine the relationship with p53 mutations, polymorphisms
and HPV infection.
In conclusion, our studies demonstrate a clear association
between Tp53 mutations and squamous cell carcinomas. The
association with HPV infection is less well defined partly due to the
high incidence of HPV infection in normal and tumor biopsies. It
is possible that specific HPV types are causally linked with
cutaneous squamous cell carcinomas and were not identified in
this study since all HPV infections were classified together. Studies
monitoring other aspects of HPV infection including viral load,
integration and expression may better define a causal link with
cutaneous squamous cell carcinoma. Importantly we found that
the expression of the common Tp53 polymorphism Tp53-72P is
protective against the development of cutaneous squamous cell
carcinomas arising in elderly white males. In addition, we found a
significant inverse correlation between Tp53 mutations and HPV
DNA in the tumors stratified for Tp53-72 polymorphism
suggesting two separate mechanisms of carcinogenesis one
dependent on Tp53 mutations and the other dependent on
HPV infection.
Supporting Information
Table S1 Primers for Tp53 analysis. The Tp53 mRNA
template was transcribed into cDNA with MLV reverse
transcriptase, using the listed cDNA amplification primers (1) to
generate a 1142 bp product. Nested PCR reactions were carried
out to amplify an 873 bp fragment from exon 4 to exon 8 using the
nested PCR amplification primers (2). Both strands of the
amplified cDNA were then sequenced using the specific
sequencing primers (3).
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